TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01211522
Drug: Haloperidol
Normalized name: Haloperidol
DrugBank: Haloperidol (DB00502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
Study: NCT00003297
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003297
Drug: thiotepa
Normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01211522
Drug: Ziprasidone
Normalized name: Ziprasidone
DrugBank: Ziprasidone (DB00246)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
Study: NCT00003297
Drug: topotecan hydrochloride
Normalized name: Topotecan Hydrochloride
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02645890
Drug: CKD-397
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm A:Tamsulosin/ Tadalafil Fixed dose combination
Study: NCT02645890
Drug: TD+TM
Normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Arm B: Tamsulosin/ Tadalafil Coadministration
Study: NCT03528941
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients who received lamivudine to prevent hepatitis B
Study: NCT00517582
Drug: HOE-140
Normalized name: CASTOR OIL 3 mg in 30 mg / ROSEMARY 4.5 mg in 30 mg / TOCOPHEROL 9 mg in 30 mg TOPICAL LIQUID [HOEGOA Herbal Hair Growth OiI]
DrugBank: Castor oil (DB11113)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous at time 0 and 6 hours
Study: NCT02827526
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02827526
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03336346
Drug: dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: HIV integrase strand transfer inhibitor used in combination ART
Study: NCT03336346
Drug: Efavirenz
Normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: non-nucleoside reverse transcriptase inhibitor used in combination ART
Study: NCT02767531
Drug: Orlistat
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
Study: NCT00302627
Drug: Pamidronate
Normalized name: Pamidronate
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60mg or 90mg given at baseline, 6,12,18, and 24 months
Study: NCT00302627
Drug: vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: baseline, 6,12 months
Study: NCT00302627
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: baseline, 6,12 months
Study: NCT00382356
Drug: Dutasteride
Normalized name: Dutasteride
DrugBank: Dutasteride (DB01126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: once daily dosing of 0.5mg Dutasteride for 12 months
Study: NCT02949258
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
Study: NCT02949258
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
Study: NCT02949258
Drug: epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
Study: NCT02949258
Drug: S1
Normalized name: LS11
DrugBank: LS11 (DB05918)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
Study: NCT03147963
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel will be given until progression or patient intolerance
Study: NCT03612219
Drug: Apatinib mesylate tablet
Normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment by apatinib mesylate tablet to local advanced nasopharyngeal carcinoma after IMRT with concurrent chemotherapy.the dose of apatinib mesylate tablet was 250 mg,orally,qd,28 days for an observation period,six cycles.
Study: NCT03612219
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent chemotherapy: patients received intravenous cisplatin 80mg/m2(D1-3), 3-week chemotherapy for 3 cycles.
Study: NCT03587441
Drug: Neostigmine Methylsulfate
Normalized name: Neostigmine Methylsulfate
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 µg Neostigmine Methylsulfate intrathecal in 0.2 ml of Dextrose 5% solution
Study: NCT03587441
Drug: Dextrose 5% in water
Normalized name: LVP solution Dextrose 5% in Water intravenous solution
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intrathecal
Study: NCT00369304
Drug: pharmacokinetic (how the body absorbs and eliminates) interaction
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03393520
Drug: AVP-786
Normalized name: AVP 21D9
DrugBank: AVP-21D9 (DB17798)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral capsules
Study: NCT00630344
Drug: Bicalutamide
Normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02148614
Drug: Libramed
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
Study: NCT01939327
Drug: Lenalidomide/Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT04371939
Drug: Romiplostim
Normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive romiplostim at an initial dose of 9 µg/kg subcutaneously per week for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response cross over to arm II.
Study: NCT04371939
Drug: Eltrombopag
Normalized name: Eltrombopag
DrugBank: Eltrombopag (DB06210)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive eltrombopag at a dose of 2-3mg/kg daily (ages 0 to 5 years) and 75 mg/daily (\>6 years) for at least 1 month depending on their response to study drug.~Patients failing to achieve a complete platelet response switch to arm I.
Study: NCT00858208
Drug: pegaptanib sodium
Normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegaptanib sodium intravitreal injection every 6 weeks for 2 years
Study: NCT03992911
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toripalimab was administered intravenously at 240 mg on day 1 every 2 weeks in one course.
Study: NCT03992911
Drug: Etoposide, Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 with Cisplatin at 80 mg per square meter on day 1 every 3 weeks in one course.
Study: NCT03992911
Drug: Etoposide, Carboplatin
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide was administered intravenously at 100 mg per square meter on day 1,2,3 and Carboplatin with AUC 5mg/mL/min on day 1 every 3 weeks in one course.
Study: NCT00249483
Drug: Venlafaxine
Normalized name: Venlafaxine
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxiine 300mg/day
Study: NCT00740285
Drug: Lidocaine 2% without vessel constrictor
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours~* next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
Study: NCT02481882
Drug: Prohance (Gadoteridol)
Normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
Study: NCT00716573
Drug: everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 0,75 mg bid, 24 months
Study: NCT00657774
Drug: Oral Prednisone 10mg
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
Study: NCT03007342
Drug: Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet
Normalized name: Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01743651
Drug: arbaclofen
Normalized name: Arbaclofen
DrugBank: Arbaclofen (DB08891)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg/day as 20 mg arbaclofen ER administered orally 2 times per day
Study: NCT01743651
Drug: baclofen
Normalized name: Baclofen
DrugBank: Baclofen (DB00181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 80 mg/day as 20 mg baclofen administered orally 4 times per day
Study: NCT04377997
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given the established link between endothelial dysfunction and thrombosis in patients with cardiovascular disease9, 10 and the association between coagulopathy and adverse outcomes in patients with sepsis11, the association between increased coagulation activity, end-organ injury, and mortality risk may represent a modifiable risk factor among COVID-19 patients with critical illness. Therefore, we propose to conduct a randomized, open-label trial of therapeutic anticoagulation in COVID-19 patients with an elevated D-dimer to evaluate the efficacy. Most patients will receive low molecular weight heparin however, unfractionated heparin (UFH) will be administered for those with morbid obesity or moderate to severe renal dysfunction.
Study: NCT01581853
Drug: Lopinavir/ritonavir 800 mg / 200mg
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
Study: NCT00087490
Drug: linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00087490
Drug: vancomycin
Normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01579149
Drug: plerixafor
Normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
Study: NCT03165383
Drug: Bupivacaine (Transversus Abdominis Plane Block)
Normalized name: Ivy Block
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
Study: NCT03165383
Drug: Intravenous Patient Controlled Analgesia (PCA) Morphine
Normalized name: lauryl PCA
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
Study: NCT03432533
Drug: romosozumab HCP administration with PFS
Normalized name: romosozumab
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 210 mg romosozumab SC QM by HCP administration with 2 PFS
Study: NCT02742051
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant endocrine therapy
Study: NCT02742051
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy
Study: NCT02742051
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy
Study: NCT04095793
Drug: ampreloxetine
Normalized name: Ampreloxetine
DrugBank: Ampreloxetine (DB15348)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, QD
Study: NCT02745769
Drug: Ramucirumab
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered IV
Study: NCT02745769
Drug: Merestinib
Normalized name: Merestinib
DrugBank: Merestinib (DB12381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02745769
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered orally
Study: NCT01857453
Drug: carboplatine
Normalized name: Carboplatine
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
Study: NCT03366597
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.5%-3% Sevoflurane will be given during the cardiac surgery except cardiopulmonary bypass.
Study: NCT01857453
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
Study: NCT00006265
Drug: ara-C
Normalized name: Ara-C
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 g/sq m IV infusion over 3 hours Days 1-5
Study: NCT04434105
Drug: platlet rich plasma (PRP)
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) promotes angiogenesis, neurogenesis, and nerve regeneration, also it could reduce swelling and inflammation of the flexor tenosynovitis.
Study: NCT04434105
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40 mg triamcinolone acetonide
Study: NCT00276328
Drug: Diosmectite (Smecta®)
Normalized name: Umecta
DrugBank: Montmorillonite (DB13654)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04434105
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline
Study: NCT03124108
Drug: Elafibranor 80 mg
Normalized name: elafibranor 80 MG
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two coated tablets daily for 12 weeks
Study: NCT03124108
Drug: Elafibranor 120 mg
Normalized name: elafibranor
DrugBank: Elafibranor (DB05187)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two coated tablets daily for 12 weeks
Study: NCT03619837
Drug: Sofosbuvir/Velpatasvir
Normalized name: SOFOSBUVIR/VELPATASVIR
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir/Velpatasvir starting early post-transplant for total of 12 weeks.
Study: NCT02744508
Drug: palonosetron
Normalized name: Palonosetron
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02744508
Drug: palonosetron with dexamethasone
DrugBank: Palonosetron (DB00377)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01839253
Drug: b-blocker(Atenolol)
Normalized name: Atenolol
DrugBank: Atenolol (DB00335)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03619837
Drug: Sofosbuvir/Velpatasvir/Voxilaprevir
Normalized name: sofosbuvir/velpatasvir/voxilaprevir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Only for patients who fail initial treatment with Sofosbuvir/Velpatasvir.~Dosage: 400mg/100mg/100mg daily for 12 weeks.
Study: NCT01769482
Drug: Udenafil
Normalized name: udenafil
DrugBank: Udenafil (DB06267)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
Study: NCT03432572
Drug: Pyridium
Normalized name: Pyridium
DrugBank: Phenazopyridine (DB01438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a urine discoloration agent
Study: NCT03432572
Drug: Riboflavin
Normalized name: Riboflavin
DrugBank: Riboflavin (DB00140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a urine discoloration agent
Study: NCT00288236
Drug: Rimonabant (SR141716)
Normalized name: rimonabant
DrugBank: Rimonabant (DB06155)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT02127918
Drug: ESES treated with clobazam
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
Study: NCT01453530
Drug: Sugammadex
Normalized name: Sugammadex
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A single dose of sugammadex 2 mg/kg iv
Study: NCT01453530
Drug: Neostigmine/Glycopyrrolate
DrugBank: Neostigmine (DB01400)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
Study: NCT04824131
Drug: Oral cabotegravir (CAB)
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30 mg tablets
Study: NCT04824131
Drug: CAB LA
Normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
Study: NCT00504010
Drug: Arnica Montana
Normalized name: Arnica montana
DrugBank: Arnica montana (DB14297)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied to lower extremity once a day for 3 days
Study: NCT00807014
Drug: Duac Gel
Normalized name: benzoyl peroxide / clindamycin phosphate Topical Gel [Duac]
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duac® Gel will be applied to the face once daily at night, for 12 weeks.
Study: NCT00021242
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous IV infusion
Study: NCT04824131
Drug: Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300 mg/200 mg fixed-dose combination tablets
Study: NCT00807014
Drug: Differin gel
Normalized name: adapalene Topical Gel [Differin]
DrugBank: Adapalene (DB00210)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Differin Gel will be applied to the face once daily at night, for 12 weeks.
Study: NCT02035124
Drug: Cabazitaxel
Normalized name: Cabazitaxel
DrugBank: Cabazitaxel (DB06772)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02105350
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02105350
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03480971
Drug: Tempol
Normalized name: Tempol
DrugBank: Tempol (DB12449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product is Tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-1-oxyl) oral solution. Tempol solution is an orange-colored, aqueous solution containing 7% Tempol along with xanthan gum, xylitol, aspartame, acesulfame potassium, sodium saccharin, alcohol, peppermint and wintergreen oils.
Study: NCT00769418
Drug: odanacatib
Normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.~Panel A: odanacatib tablets 2.5 mg qd for 14 days.~Panel B: odanacatib tablets 5 mg qd for 14 days.~Panel C: odanacatib tablets 10 mg qd for 14 days.~Panel D: odanacatib tablets 25 mg qd for 14 days.~Panel E: odanacatib tablets 0.5 mg qd for 21 days.~Panel F: odanacatib tablets 2.5 mg qd for 21 days.~Panel G: odanacatib tablets 10 mg qd for 21 days.
Study: NCT03168438
Drug: Letetresgene autoleucel
Normalized name: Letetresgene autoleucel
DrugBank: Letetresgene autoleucel (DB17233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion
Study: NCT03168438
Drug: Letetresgene autoleucel with pembrolizumab
Normalized name: Letetresgene autoleucel
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
Study: NCT03168438
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
Study: NCT03168438
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is available as an IV infusion
Study: NCT00642161
Drug: budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02707328
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02707328
Drug: nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01289171
Drug: Glycolic acid
Normalized name: Glycolic Acid
DrugBank: Glycolic acid (DB03085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.